Abstract
The interferon response is a potent antiviral defense mechanism, but its effectiveness depends on its timing relative to viral replication. Here, we report viral replication and host response kinetics in patients at the start of SARS-CoV-2 infection and explore the impact of these kinetics experimentally. In both longitudinal patient nasopharyngeal samples and airway epithelial organoids, we found that SARS-CoV-2 initially replicated exponentially with a doubling time of ∼6hr, and induced interferon stimulated genes (ISGs) with delayed timing relative to viral replication. Prior exposure to rhinovirus increased ISG levels and blocked SARS-CoV-2 replication. Conversely, inhibiting ISG induction abrogated interference by rhinovirus and enhanced SARS-CoV-2 replication rate. These results demonstrate the importance of initial interferon-mediated defenses in determining the extent to which SARS-CoV-2 can replicate at the start of infection and indicate that biological variables that alter the airway interferon response, including heterologous induction of innate immunity by other viruses, could profoundly impact SARS-CoV-2 susceptibility and transmission.
Competing Interest Statement
Dr. Foxman is an inventor on a pending patent application WO2019/217296 A1 and Dr. Foxman and Dr. Landry are inventors on pending patent application WO2018/071498 Al.
Funding Statement
Fast Grants from Emergent Ventures to E.F.F. - China Scholarship Council Yale World Scholars Fellowship to B.W. - Gruber Foundation Fellowship to T.A.W. - NIH T32AI007019 to T.A.W.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The use of clinical samples and data in this study was approved by the Yale Human Research Protection Program Institutional Review Board (Protocol ID #200002765). Procedures for testing residual clinical samples and recording linked patient data, followed by sample and data de-identification, were evaluated and the requirement for specific patient consent was waived. In vitro experiments used primary human cells obtained from Lonza Bioscience (Walkersville, Maryland, U.S.A.). Lonza guarantees that all tissue utilized for human cell products is ethically obtained with donor informed consent in accordance with processes approved by an Institutional Review Board or comparable independent review body.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version was edited to make the rationale clearer in the introduction.
Data Availability
We plan to deposit RNASeq data sets in the GEO database and this data will be publicly available at the time of study publication in a peer-reviewed journal.
